G. Adler

M.P. Manns

W. Schmiegel

C. Beglinger

S. Müller-Lissner

Hier finden Sie den aktuellen Wissensstand der Gastroenterologie didaktisch klar und übersichtlich zum schnellen Nachschlagen. Inhalt und Gliederung sind auf die Weiterbildungsinhalte abgestimmt. - Symptom-orientierter Aufbau: Motilitäts- und funktionelle Störungen, entzündliche Erkrankungen, Tumore und Stoffwechselerkrankungen - Pathophysiologische Grundlagen - Klinische Krankheitsbilder, Diagnostik und Therapie - Wichtige Leitsymptome und Notfallsituationen knapp und prägnant auf einen Blick Ein Referenz-Werk, das Ihnen den raschen Überblick in Klinik und Praxis erleichtert und präzise Detail-Informationen für Ihre Weiterbildung bietet.

Klinische Gastroenterologie und Stoffwechsel

S. Gupta

J. Klempnauer

Peter L.M. Jansen

In recent years there has been an increasing need for transplantation, but the number of donor livers available has increased only slightly, despite intensive public relations activities. New concepts in the field of transplantation, for instance the transplantation of living donor organs or the splitting of organs, are urgently required, to safeguard the treatment of patients with severe liver disease. The development and clinical application of cell therapy for patients with liver disease could soon present a significant enhancement of the therapeutic options. The aim of such cell therapy is to repair or improve the biological function of the chronically and acutely damaged liver. Even though systematic trials are not available, individual case reports and small series already show promising clinical results. Present concepts of cell therapy for liver diseases based on the use of primary hepatocytes have recently been considerably extended through new data on the biology of stem cells. The adult haematopoetic stem cell as a pool for hepatocyte grafts - what would be the perspectives for the clinical application? This book is the proceedings of the Falk Symposium No. 126 on `Hepatocyte Transplantation' (Progress in Gastroenterology and Hepatology Part III) held in Hannover, Germany, October 2-3, 2001, and is a forum for basic research, but also for questions concerning clinical applications in the field of hepatocyte transplantation.

Hepatocyte Transplantation

N. Hiyashi

Nariyuki Hayashi

In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe. This book, the proceedings of the Falk Workshop on 'Prevention of Progression in Chronic Liver Disease - An Update on SNMC (Stronger Neo-Minophagen C)' (Part IV of the XII Falk Liver Week, in honour of Hans Popper's 100th birthday) held in Freiburg, Germany, on 22 October 2003, is devoted to the understanding of basic mechanisms of fibrogenesis, the state of the art of non-invasive markers of disease progression that may substitute liver biopsy in the future, and of other predictive parameters indicating disease progression, in particular the development of hepatocellular carcinoma. All these problems are particularly relevant for chronic hepatitis C. A better characterization of so-called non-responders for the treatments available is crucial for the development of new strategies preventing or postponing disease progression. Such strategies should influence fibrogenesis and, thus, cirrhosis formation as well as the development of life threatening complications of liver cirrhosis, including hepatocellular carcinoma. In this volume, the available information on SNMC as an approach to prevent progression of chronic liver disease is discussed by several internationally renowned authors who report on the mechanisms of liver fibrogenesis and fibrolysis, on non-invasive markers of disease progression, and on hepatocellular carcinoma as one of the major complications of liver cirrhosis nowadays. Finally, experts from Japan report on their knowledge and experience concerning the drug SNMC/Glycyrrhizine in the prevention of cirrhosis and HCC, and first study results from Europe are presented.

An Update on SNMC (Stronger Neo-Minophagen C). In Honour of Hans Popper's 100th Birthday

Prevention of Progression in Chronic Liver Disease

M.P. Manns

Books

Your next favorite book is out there